ABSTRACT
INTRODUCTION
Fifty percent of patients with colorectal carcinoma (CRC) develop recurrence after successful surgery, presumably due to micrometastases (1) . Adjuvant chemotherapy may improve the absolute survival by 5-6% in stage III CRC, whereas its beneficial effect in stage II disease is controversial (1) . Vaccine therapy might be an alternative treatment strategy to improve the prognosis of CRC patients.
The tumor-associated antigen (TAA) Ep-CAM (epithelial cell adhesion molecule; Ref. 2 ) is expressed at a high level by a large number of epithelial neoplasias, including CRC. Normal epithelial cells express Ep-CAM at a lower density restricted to the basolateral cell surface (2) . CRC patients, but not healthy donors or patients with inflammatory bowel disease, mount a natural immune response against Ep-CAM (3, 4). Treatment with monoclonal antibody (mAb) 17-1A (anti-Ep-CAM) may improve the survival of patients with resected stage III CRC (5) (6) (7) . Vaccination with viral vectors encoding Ep-CAM could induce Ep-CAM-specific immune responses in animal models and humans (8, 9) . Immunization with Ep-CAM protein produced in a baculovirus expression system and conjugated to alum has also elicited humoral and cellular immunity in CRC patients (10) .
Anti-idiotypic antibody (anti-Id) mimicking a TAA may serve as a surrogate antigen (Ag) and induce TAA-specific immunity (11) . Vaccination with anti-Ids mimicking Ep-CAM has elicited Ep-CAM-specific humoral and cellular immune responses in cancer patients (8, 12) . Anti-Id or the Ep-CAM protein has, however, not been tested in combination with the potent adjuvant granulocyte macrophage colony-stimulating factor (GM-CSF), which has been shown to significantly augment both humoral and cellular immune responses against weakly immunogenic Ags (13). It is also controversial whether an anti-Id or the bona fide Ag is more potent as a vaccine (14, 15) .
Optimal antitumor immunity entails the induction of Agspecific Th1-biased humoral and cellular effector functions (16) . Various in vitro assays are used to monitor Ag-specific immune responses including proliferation assay, ELISPOT, and multiparameter flow cytometry (17) . In humans, type 1 immunity is associated with IgG1 and IgG3, whereas type 2 immunity is associated with IgG4 antibody (Ab) responses (18) . Thus, analysis of the Ag-specific IgG subclass response may serve as a surrogate marker for type 1 and 2 immunity.
The present study constitutes a basis for future development of a vaccination approach targeting Ep-CAM. The objectives were to evaluate in CRC patients the safety and immunogenicity of an Ep-CAM protein and a human anti-Id vaccine in combination with GM-CSF and to identify MHC-restricted immunogenic epitopes of the Ep-CAM molecule in a genetically diverse population.
PATIENTS AND METHODS
Patients. Thirteen patients were enrolled in this study. Eligibility criteria included histopathological diagnosis of Ep-CAM-positive adenocarcinoma of the colon or rectum, American Joint Committee on Cancer stage II-IV disease, and resection of the primary tumor (and metastasis in stage IV) without evidence of remaining macroscopic disease. Patients were required to have a Karnofsky performance status of Ն80% and adequate hepatic and renal function. Exclusion criteria were as follows: pregnancy or nursing; HIV seropositivity; alcohol or drug abuse; autoimmune disease; known hypersensitivity to insect cells, baculovirus, or GM-CSF; active infection; chronic systemic disorder; or chemo-or radiotherapy or other immunosuppressive agent within 30 days before study entry. Patients were included before routine adjuvant chemotherapy for stage III colon cancer was introduced in Sweden. The study was approved by the Ethical Committee of the Karolinska Institute. All patients were treated after informed consent.
Before entry into the study, a complete case history was obtained, and physical exam and blood tests including hemoglobin, white blood cell count with differentials and platelet counts, serum creatinine and electrolytes, serum protein electrophoresis, tests for liver function, thyroid function, serum tumor markers [carcinoembryonic antigen (CEA), CA19-9, CA50], and standard urine analysis were performed. HLA typing was done at the Tissue Typing Laboratory, Huddinge University Hospital. A chest X-ray and CAT scan of the abdomen were performed as well. During follow-up, patients were regularly checked for performance status and vital signs, routine blood hematology and chemistry analyses, standard urine analysis, thyroid function tests, and serum tumor markers. Adverse events were assessed according to the National Cancer Institute Common Toxicity Criteria Version 2.0. 4 Vaccination was discontinued if disease progression occurred, and patients received standard therapy (surgery, chemotherapy, or radiotherapy).
Vaccine Preparations. The extracellular domain of the Ep-CAM protein was purified using an immunoaffinity column coupled with the anti-Ep-CAM mAb GA733 (Centocor, Malvern, PA) from supernatants of cultured Spodoptera frugiperda insect cells infected with a recombinant Ep-CAM baculovirus construct as described elsewhere (19) . The only modifications to the previously described method were that serum-free medium SF900II (GIBCO, Paisley, Scotland) was used during the whole culture period and detergent was omitted from the elution buffer in immunoaffinity chromatography.
The human anti-Id (IgG1) mimicking Ep-CAM (ab 2 ␤) was produced by an Epstein-Barr virus-immortalized human lymphoblastoid cell line derived from a patient treated with murine mAb 17-1A (20, 21) . Anti-Id was purified on protein A and mAb Trap G columns (Pharmacia, Uppsala, Sweden) as described previously (20, 21) .
Purity of the Ag preparations was confirmed by SDS-PAGE and electrophoresis. Immunoreactivity of the products was checked by enzyme-linked immunosorbent assay (ELISA) and Western blot (19 -21) . Tests for sterility, endotoxin, and viruses were performed according to the protocol described previously (21) .
Vaccination Schedule. Patients were randomized into one of the two vaccination schedules receiving intradermal/ subcutaneous injections of Ep-CAM protein (400 g/dose; n ϭ 7) or anti-Id (500 g/dose; n ϭ 6) at weeks 0, 2, and 6. Patients received concomitant GM-CSF (75 g/day; Leucomax; Schering-Plough, Kenilworth, NJ) for 4 consecutive days at each immunization. The first dose of GM-CSF was given the day before the vaccine. Ags and GM-CSF were injected to the same site in the deltoid region. Patients who exhibited a negative Ep-CAM-specific proliferative T-cell response for a prolonged time and gave consent received additional booster vaccinations (see "Results"). Patients were clinically followed and immune monitored at regular intervals (see "Results").
Monoclonal Antibodies, Control Antigens, Peptides, and Colorectal Carcinoma Cell Lines. The humanized mAb 3622W94 recognizing Ep-CAM was a kind gift from Dr. J. H. Ellis (GlaxoSmithKline, Stevenage, United Kingdom). Mouse antihuman HLA-ABC mAb (clone W6/32; DAKO, Glostrup, Denmark), mouse antihuman HLA-DR mAb (clone G46-6; BD PharMingen, Mountain View, CA), and purified mouse IgG2a as a control (BD PharMingen) were used in blocking experiments (10 g/ml).
As controls for the baculovirus recombinant Ep-CAM protein, a baculovirus control protein (BCP), baculovirus recombinant CEA (Protein Sciences Corp., Meriden, CT), and a baculovirus recombinant HIV gp160 (kindly provided by Dr. B. Wahren; Swedish Institute for Infectious Disease Control, Karolinska Institute, Stockholm, Sweden) were used. Production of BCP and CEA has been described elsewhere (22) . As controls for the human anti-Id, a human mAb preparation (IgG1; Ref. 12) and human polyclonal IgG (Gammaglobulin; Pharmacia, Stockholm, Sweden) were used.
The protein sequences of the complete human Ep-CAM (23) and the complementarity determining regions (CDRs) of anti-Id (24) were submitted to online databases 5 (25, 26) Detection of IgG and IgG Subclass Antibodies against Ep-CAM (ELISA). Abs against Ep-CAM were analyzed as described previously (9) , with recombinant gp160 protein used as control Ag. Wells were coated with 2.5 g/ml Ep-CAM and gp160 protein. Serum samples were assayed at 1:50 and 1:100 dilutions. The anti-Ep-CAM mAb 3622W94 (0.1-100 ng/ml) was used as a standard. The anti-Ep-CAM IgG concentration [arbitrary ELISA units (EU)/ml] was calculated from the standard curve.
Sera of healthy blood donors (n ϭ 30) were used as controls. The median age of the controls (22 males and 8 females) was 57 years (range, 48 -70 years), and the IgG titers against Ep-CAM were 0.871 ϩ 0.817 EU/ml (mean ϩ 2 SD). Based on these results, the threshold level for a positive response was set to Ͼ1.688 EU/ml. IgG titers against gp160 in healthy controls and patients before immunization were 1.056 Ϯ 0.066 and 0.411 Ϯ 0.162 (mean Ϯ SE), respectively.
Ep-CAM-specific IgG1, IgG2, IgG3, and IgG4 Abs were determined as described previously (28) . The coating concentration for Ep-CAM and gp160 was 2 g/ml. All serum samples were initially assayed at 1:40 dilution, except in the case of IgG4, for which a 1:8 dilution was used. High-titered sera were further assayed at higher dilutions. The Ab concentrations were calculated from standard curves established from chimeric IgG1, IgG2, IgG3, and IgG4 anti-5-iodo-4-hydroxy-3-nitrophenacetyl acid hapten Abs using bovine serum albumin (BSA)-5-iodo-4-hydroxy-3-nitro-phenacetyl acid conjugate (10 g/ml) as coating Ag (28) . Taking serum dilution into account and correcting for background, the sensitivity of the assay was 8 (IgG1), 4 (IgG2 and IgG3), and 0.4 EU/ml (IgG4). This procedure permits comparison of results in a semiquantitative way, where 1 EU approximately corresponds to 1 ng of Ab.
Western Blot. Proteins (20 g/ml) and molecular mass standards (SeeBlue; Novex, San Diego, CA) were separated by SDS-PAGE on 4 -12% Bis-Tris NuPAGE precast gradient gels (Novex) under reducing or nonreducing conditions according to the manufacturer's instructions. Proteins were electroblotted for 1 h onto a nitrocellulose membrane (0.45 m; Novex), which was subsequently blocked (1 h) with PBS containing 4% milk powder (Semper, Stockholm, Sweden), 2% BSA (Sigma-Aldrich, St. Louis, MO), and 0.05% Tween 20. Membranes were incubated overnight at 4°C with either humanized anti-Ep-CAM mAb 3622W94 (IgG1; 1 g/ml), a control human mAb preparation (IgG1; 1 ug/ml), or serum samples (1:100) diluted in blocking solution. After washing, antihuman IgG1 mAb (1:5000 dilution; Ref. 28 ) was added for 6 h at room temperature, followed by alkaline phosphatase-conjugated rabbit F(abЈ) 2 antimouse IgG Ab overnight at 4°C (28) . After washing in 0.9% NaCl, the membranes were developed with alkaline phosphatase color buffer (Bio-Rad Lab, Stockholm, Sweden). All washing steps (3 ϫ 5 min) were performed with blocking solution diluted (1:10) in PBS containing 0.05% Tween 20.
Lymphoproliferative Assay. Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized venous blood by Ficoll gradient centrifugation, and proliferative T-cell response assessed in a standard [ 3 H]thymidine incorporation assay as described previously (9) . Protein Ags were added at concentrations 1, 10, and 100 ng/ml. Twenty-three Ep-CAMderived 18-mer peptides (with 6-amino acid NH 2 -and COOHterminal overlap; Ref.
3) were also used as stimulators (1-10 g/ml). Phytohemagglutinin (PHA; 10 g/ml; Sigma), concanavalin A (10 g/ml; Amersham Bioscience, Uppsala, Sweden), purified protein derivative of tuberculin (PPD; 2.5 g/ml; Statens Seruminstitut, Copenhagen, Denmark), and tetanus toxoid (TT; 50 ng/ml; SBL Vaccine, Stockholm, Sweden) were used as positive controls. A stimulation index (SI) was calculated for each triplicate by dividing mean cpm in experimental wells by that of the background value (cells in medium alone). To control for anti-baculovirus response, the highest SI value of cells stimulated with either BCP or CEA was subtracted from that of cells stimulated with Ep-CAM in each test. SI values of IgG1 or gammaglobulin were subtracted from that of the anti-Id in a similar manner.
In healthy control donors, the highest SI values induced by Ep-CAM (n ϭ 34) and anti-Id (n ϭ 29) were 1.7 ϩ 1.2 and 1.6 ϩ 1.2 (mean ϩ 2 SD), respectively. The corresponding value (n ϭ 21) for the 18-mer Ep-CAM-derived peptides was 2.1 ϩ 1.4. Based on these results, the threshold level for a positive proliferative T-cell response was set to Ͼ3.0 for protein Ags and Ͼ3.5 for peptides. SI values against PHA, concanavalin A, PPD, and TT in patients were 295 Ϯ 74, 84 Ϯ 23, 85 Ϯ 23, and 9 Ϯ 6 (mean Ϯ SE), respectively. The corresponding figures in healthy controls were 94 Ϯ 24, 101 Ϯ 39, 192 Ϯ 50, and 40 Ϯ 16, respectively. The differences in results between patients and controls were statistically not significant, except for TT (P ϭ 0.004).
Enzyme-Linked Immunospot Assay (ELISPOT) for Detection of Interferon-␥-Producing Cells. Cryopreserved PBMCs were thawed and allowed to recover overnight at 37°C in humidified air with 5% CO 2 . ELISPOT assay was performed as described previously (9) . Briefly, interferon (IFN)-␥ secretion was assessed on nitrocellulose membrane bottomed-plates (Millipore, Bedford, MA) using a mouse antihuman IFN-␥ mAb pair, clone 1-D1K (10 g/ml) and 7-B6-1 (1 g/ml; Mabtech AB, Stockholm, Sweden). PBMCs (10 5 cells/ well) were incubated for 20 h in the presence of Ep-CAM, BCP and CEA proteins (100 and 1000 ng/ml) as well as Ep-CAMderived and control peptides (10 g/ml; Table 1 ). In some tests, irradiated (6000 rads) CRC cells (10 4 cells/well) were used as stimulators. Cells stimulated with PHA (10 g/ml) and PPD (2.5 g/ml) served as positive controls. Streptavidin-alkaline phosphatase (1:1000; Mabtech), followed by 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium (Sigma) was used for development of the color reaction. Results were quantified using an automated computer-assisted video imaging analysis system (Axioplan 2; Carl Zeiss Vision).
Results are expressed as the number of spot-forming units (SFU) per 10 6 cells in 6 experimental wells (mean Ϯ SE) after subtraction of the background value (cells in medium alone). In some tests, the numbers of replicates were reduced due to lack of cells. Results were considered positive if the number of SFU in experimental wells was significantly (P Ͻ 0.05) greater than the background value and was at least twice that of the background. SFU of healthy control donors against Ep-CAM (n ϭ 24), BCP (n ϭ 14), and CEA (n ϭ 14) were 11 Ϯ 3, 6 Ϯ 3, and 11 Ϯ 5 per 10 6 PBMCs (mean Ϯ SE), respectively. The corresponding figures (n ϭ 10) for anti-Id, IgG1, and gammaglobulin were 14 Ϯ 4, 16 Ϯ 5, and 19 Ϯ 9 per 10 6 PBMCs, respectively. No positive response against any of these proteins was detected in healthy controls. HLA-typed healthy controls (n ϭ 10) were also tested against Ep-CAM-derived peptides (Table 1) . A positive response was detected against p 29 -43 in one control and against p 113-127 in another donor. The other peptides were negative.
Intracellular Interferon-␥ and Perforin Detection by Four-Color Flow Cytometry. PBMCs (1 ϫ 10 6 cells/ml) were incubated in the presence of Ep-CAM or BCP (1,000 ng/ml) for 16 h at 37°C in humidified air with 5% CO 2 . PBMCs with or without phorbol 12-myristate 13-acetate (50 ng/ml; Sigma) and ionomycin (250 ng/ml; Sigma) served as positive and negative controls, respectively. Brefeldin A (Sigma) was added (10 g/ml), and incubation continued for an additional 4 h. Cells were washed and incubated in 4% paraformaldehyde (Sigma) for 10 min on ice followed by washing in PBS containing 1% BSA and 0.1% NaN 3 . Surface staining was carried out by incubation for 30 min on ice in dark with mAb (BD PharMingen) mixtures as follows: (a) anti-CD3-APC, anti-CD8-PerCP-Cy5.5, and anti-CD4-R-PE; and (b) anti-CD3-APC, anti-CD8-PerCP-Cy5.5, and anti-CD56-R-PE. Isotypematched Abs served as negative controls. After washing, cells were incubated in FACS Permeabilizing Solution (BD Immunocytometry Systems, San Jose, CA) for 10 min at room temperature. Cells were washed and stained with anti-IFN-␥-FITC or anti-perforin-FITC or isotype control-FITC mAbs (all from BD PharMingen) for 30 min on ice in the dark. Anti-vimentin-FITC Ab (kindly provided by Dr. R. Lenkei, CALAB ResearchNova Medical, Stockholm, Sweden) was used to test for the efficiency of permeabilization. Cells were washed and resuspended in 0.5% paraformaldehyde in PBS, and data acquisition was performed using a flow cytometer (FACScalibur). A total of 200,000 events gated on the basis of forward and side scatter for lymphocytes were collected. Data were analyzed using CellQuest software (BD Immunocytometry Systems).
Statistical Analysis. The nonparametric WilcoxonMann Whitney two-tailed rank-sum test was used for compar-ison of the number of SFU (ELISPOT) in replicates of experimental versus background wells.
RESULTS
Patient Characteristics. Thirteen patients who underwent surgical resection for adenocarcinoma of the colon (n ϭ 11) or rectum [n ϭ 2 (American Joint Committee on Cancer stages II-IV)] with no evidence of remaining macroscopic disease were included in the study (Table 2 ). Median time from surgery to start of immunization was 4 months (range, 1-44 months). The patients were immunized with Ep-CAM protein (n ϭ 7) or human anti-Id mimicking Ep-CAM (n ϭ 6) at weeks 0, 2, and 6 in conjunction with GM-CSF. In addition to the three initial immunizations, two patients in the Ep-CAM vaccine group and four patients in the anti-Id vaccine group received booster doses (see "Patients and Methods;" Table 2) .
Adverse Events. Vaccination was well tolerated (Table  3) . Each patient developed injection site reactions, which were of grade 2 in 80% of the patients and grade 1 in 20% of the patients. These resolved within a week. Multiple injections (Ͼ5) were associated with prolonged (up to 42 weeks) redness and swelling. Only mild (grade 1) systemic adverse events were noted. One patient, 2.5 years after vaccination with the Ep-CAM protein, developed a mild autoimmune thyroiditis. The patient received a low-dose thyroid hormone substitution. The symptoms subsequently resolved, and no further treatment was required.
Ep-CAM-Specific IgG Response. None of the patients had Abs against Ep-CAM before vaccination. All patients immunized with the Ep-CAM protein elicited an Ep-CAM-specific IgG response (Fig. 1A) . The highest Ab titers were seen after the third vaccine dose, which was followed by a gradual decrease. No specific anti-Ep-CAM Abs were detected in any of the patients immunized with anti-Id.
The IgG Abs induced by Ep-CAM vaccination were predominantly of IgG1 type with a moderate IgG3 subclass response (Fig. 1B) . A weak IgG2 response was also elicited. Only the IgG1 subclass was detected after 1 year. No IgG4 Abs were Abbreviations: AJCC, American Joint Committee on Cancer; RT, preoperative radiotherapy. * Therapy before immunization except for surgical resection of the tumor. † All patients received three intradermal/subcutaneous injections of Ep-CAM (400 g/dose) or anti-Id (500 g/dose) at weeks 0, 2, and 6 together with GM-CSF (75 g/day, for 4 consecutive days at each immunization). Six patients received booster vaccinations at time points indicated within the parentheses.
‡ Localized liver metastasis was completely resected before immunization. (Fig. 2) . In one patient (patient A2), there was a switch in the IgG1:IgG4 ratio, whereas in another patient (patient A6), IgG1 remained the predominant subclass.
To verify the specificity of anti-Ep-CAM Abs, sera of patients immunized with Ep-CAM were tested in Western blot against the Ep-CAM and control proteins, respectively. Postimmune sera specifically bound to the Ep-CAM protein under both nonreducing and reducing conditions, suggesting recognition of both conformational and linear epitopes. The anti-Ep-CAM mAb 3622W94 only reacted with nonreduced Ag. Preimmune sera were negative (Fig. 3) .
Ep-CAM-Specific Proliferative T-Cell Response. Patients were regularly monitored for an Ep-CAM-specific proliferative T-cell response until the test was negative at two consecutive time points (median, 2 years; range, 7-69 months). None of the patients had a specific proliferative T-cell response against the Ep-CAM or anti-Id proteins before immunization.
After vaccination, all but two patients (A7 and B5) mounted an Ep-CAM-specific proliferative T-cell response, which appeared more rapidly, was stronger, and was of longer duration in Ep-CAM-as compared with anti-Id-immunized patients (Fig.  4A) . Booster vaccination induced no significant amplification of the Ep-CAM-specific proliferative T-cell response (data not shown).
All anti-Id-immunized patients developed a proliferative T-cell response against anti-Id (Fig. 4B) , which appeared at the same time as the anti-Ep-CAM T-cell response (Fig. 4A) . The response against anti-Id was, however, sustained for a longer time period.
Patients in both immunization groups also mounted a proliferative T-cell response against 18-mer Ep-CAM-derived peptides. A strong antipeptide response was usually associated with a potent proliferative T-cell response against the Ep-CAM and anti-Id proteins (data not shown).
The proliferative T-cell response against the Ep-CAM protein could be significantly inhibited by mAbs against MHC class I and II molecules (data not shown), suggesting the induction of 
Ep-CAM-specific T cells within both CD4
ϩ and CD8 ϩ T-cell subsets.
Interferon-␥-Producing Cells against the Ep-CAM Protein and Ep-CAM-Derived Peptides (ELISPOT).
PBMCs were tested before and at an average of four different time points after vaccination for IFN-␥-producing T cells. None of the patients had a specific IFN-␥ response against the whole Ep-CAM or anti-Id protein before vaccination. However, two HLA-A2 ϩ patients had a positive response against the Ep-CAM-derived peptides, p 174 -184 (patient B2) and p 255-264 (patient B3). These responses disappeared after vaccination. Four patients (patients A6, A7, B3, and B5) had a positive response against HLA-DR1/DR4-restricted p 113-127 before immunization.
After vaccination with Ep-CAM or anti-Id, specific IFN-␥-producing cells against the Ep-CAM protein as well as against various Ep-CAM-derived MHC class I-and II-restricted peptides were detected (Table 4) . Both the frequency and magnitude of the Ep-CAM-specific IFN-␥ response were similar in the two groups (data not shown). As an example, results for patient A6 after three immunizations with Ep-CAM are shown in Fig. 5A . IFN-␥ response was detected against an HLA-A2-and two HLA-DR1-restricted peptides. However, no response against the whole Ep-CAM protein was noted. As another example, results for patient A2 are shown in Fig. 5B . After the three initial Ep-CAM vaccinations, a weak IFN-␥ response was seen against an HLA-A26 -restricted peptide, but not against the whole Ep-CAM protein. After three booster vaccinations, the response against the HLA-A26 -restricted peptide was amplified, and a response against another HLA-A26 -restricted peptide as well as against the complete Ep-CAM protein emerged. As an example of anti-Id immunization, results for patient B6 are shown in Fig. 5C . A response against three different HLA-A2-restriced peptides and one HLA-B7-restricted peptide as well as the Ep-CAM protein and anti-Id was noted. Three of these peptides (p 6 -14 , p 255-264 , and p 256 -264) contain identical anchor residues and show Ͼ33% amino acid sequence homology with peptides derived from the CDRs of anti-Id. Anti-Id booster vaccination did not have a significant impact on the IFN-␥ response, except for one patient (patient B1; data not shown).
Significant IFN-␥ production was induced by Ep-CAMpositive irradiated CRC cell lines matched for HLA-A2 (LS180) or HLA-DR1 (SW837) as compared with HLA-unmatched Ep-CAM-positive CRC (SW948) and HLA-DR1
ϩ Ep-CAMnegative Burkitt lymphoma (BL-41) cells (Fig. 6) . A significant reduction (P ϭ 0.016) of the number of IFN-␥-secreting cells was observed when LS180 cells (MHC class I ϩ and class II Ϫ ) were incubated with anti-MHC class I mAb, whereas the control mAb had no significant effect (data not shown).
Phenotypes of Ep-CAM-Specific Interferon-␥-and Perforin-Producing Cells. Intracellular IFN-␥ and perforin were assessed in phenotypically characterized cells by fourcolor flow cytometry after in vitro stimulation with the Ep-CAM protein. The results for patient A1 are shown in Table 5 Overall Immune Response and Survival. A summary of the overall immune response induced by vaccination and clinical status is shown in Table 6 . The design of the study does not allow us to draw any conclusion with regard to the clinical efficacy of an Ep-CAM-specific immune response.
DISCUSSION
In this study, the safety and immunogenicity of vaccination of CRC patients with minimal residual disease using Ep-CAM as a target structure were evaluated. A recombinant Ep-CAM protein was compared with a human anti-Id vaccine mimicking Ep-CAM. As an adjuvant, GM-CSF was used.
Both vaccines were well tolerated. Systemic adverse events consisted mainly of mild constitutional symptoms. Local injection site reactions were common but not severe. The present vaccine formulations were better tolerated than Ep-CAM expressed in avipox vector (ALVAC; Ref. 9). One patient immunized with Ep-CAM developed a mild and transient autoimmune thyroiditis, which is occasionally associated with immunotherapy (29) .
Immunization with Ep-CAM, but not anti-Id, induced anti-Ep-CAM IgG Abs. Ab reactivity to both conformational and linear epitopes was noted. The subclass responses were predominantly IgG1 and IgG3. In humans, a Th1-polarized immune response is associated with IgG1 and IgG3 (18) , which are the most effective subclasses mediating phagocytosis, complement-dependent cytolysis, and Ab-dependent cellular cytotoxicity (30) . After booster vaccination, IgG4 also emerged, most likely reflecting prolonged antigenic stimulation (31) . The IgG subclass profile can be influenced by several factors. The choice of adjuvant might be important. Previous studies have shown that Ag precipitated in alum induced a Th2-polarized response (32) . Alum-precipitated recombinant CEA combined with GM-CSF induced mainly IgG1 and IgG2 but no IgG3 responses after three initial vaccinations. Repeated vaccinations, however, resulted in the increase of IgG4 titers, which is in line with the present study (33) .
Immunization with the Ep-CAM protein induced a rapid and long-lasting Ep-CAM-specific proliferative T-cell response as compared with the anti-Id vaccine, comprising both MHC class I-and II-restricted T cells. Baculovirus-derived Ep-CAM protein precipitated in alum has previously been used for vaccination of CRC patients (10) . However, the present immunization regimen induced a stronger proliferative T-cell response, which might be due to the use of GM-CSF as an adjuvant as compared with alum.
Although Abs and type 1 CD4 ϩ T cells have an important role in antitumor immunity, CD8 ϩ cytotoxic T lymphocyte (CTLs) are crucial (16) . IFN-␥-producing T cells might be considered as a surrogate marker for identification of CTL precursors (34, 35) . In this study, a long-lasting IFN-␥ T-cell response against the Ep-CAM protein and Ep-CAM-derived MHC class I-and II-restricted peptides was detected after immunization with either Ep-CAM or anti-Id. An Ep-CAMspecific T-cell response after anti-Id vaccination indicates crossreactivity between the bona fide and internal image Ags. The fact that IFN-␥-producing T cells against MHC class Irestricted peptides were induced suggests that Ep-CAM and anti-Id as exogenous protein Ags were cross-presented in vivo. Antigen-presenting cells can capture and deliver exogenous Ags into the MHC class I processing pathway, and GM-CSF may facilitate this process (36) . Interestingly, vaccination of patients with alum-precipitated Ep-CAM without GM-CSF did not induce ex vivo IFN-␥ production (10) .
It has previously been suggested that immunization with Ep-CAM protein maybe superior to anti-Id (10, 14, 37) . However, the authors used pooled delayed-type hypersensitivity and proliferative responses as a basis for comparison of cellular immune responses, despite the fact that delayed-type hypersensitivity was only assessed in Ep-CAM-immunized patients. The response rate in the two immunization groups seemed comparable in terms of both anti-Ep-CAM Abs (6 of 12 versus 7 of 13 patients) and proliferative T-cell response (3 of 12 versus 2 of 13 patients; Refs. 10 and 37). Thus, the published data do not support the conclusion made by the authors. Our data suggest that the bona fide Ag was more effective in inducing a humoral response as compared with anti-Id (7 of 7 versus 0 of 6 patients). Although there was no difference in the proliferative response rate between the two groups, the duration of the response was superior in Ep-CAM-immunized patients. However, an IFN-␥ response of a similar frequency and magnitude was induced by Ep-CAM and anti-Id.
Limited information is available with regard to immunogenic MHC class I-restricted Ep-CAM epitopes, and there is no report on class II-restricted Ep-CAM epitopes. Three HLA-A2-restricted Ep-CAM-derived peptides (p 263-271 , p 184 -192 , and p 184 -193 ) have been shown to be immunogenic (4, 27, 38) . In the present study, a number of additional functional MHC class Iand II-restricted Ep-CAM-derived peptides were identified in the context of various HLA alleles. The results also corroborate the notion that a polyclonal T-cell response was induced within both the CD4 ϩ and CD8 ϩ subsets. The immunogenicity of some peptides (p 174 -184 and p 113-127 ) was also confirmed in patients immunized with ALVAC-Ep-CAM (9) . 6 The high frequency of patients (4 of 6 patients) mounting an IFN-␥ response against the MHC class II-restricted p 113-127 before immunization might imply the involvement of this epitope in a natural T-cell response against Ep-CAM. However, a larger number of HLA-matched patients and healthy donors must be tested to verify this potentially interesting observation. An IFN-␥ response to this peptide was also seen in a healthy donor (1 of 5 healthy donors), which is not surprising because it has been indicated that T cells capable of reacting against Ep-CAM epitopes are not fully deleted from the immune repertoire (38) .
CTL effector function of CD8 ϩ T cells may correlate with the expression of CD56, and such cells express high levels of IFN-␥ and perforin (39, 40) . In response to Ep-CAM protein, we could show that various T-cell subsets secreted IFN-␥ and perforin. Both cytokines were produced primarily by CD8 ϩ T cells with or without the expression of CD56. Only CD4 ϩ T cells expressing CD56 produced perforin. There was also induction of IFN-␥ and perforin producing CD4 Ϫ CD8 Ϫ T cells, either CD56
Ϫ or CD56 ϩ , most likely representing ␦␥ T cells (41) . NK cells were also activated, probably as a bystander effect. Generation of a phenotypically and functionally diverse Ag-specific T-cell repertoire has also been reported after HER-2/neu-based vaccination (42) . A detailed characterization of Ep-CAM-specific CD56 ϩ T cells is of great interest and warranted in future studies. These cells may represent CD1d-restricted NKT cells (43) . Tumor cells engineered to secrete GM-CSF have been shown to induce expansion of CD1d-restricted T cells, which were critical for antitumor immunity in a murine model (44) .
In conclusion, the present study demonstrates that immunization with a recombinant Ep-CAM protein or anti-Id in combination with GM-CSF was safe and generated a polyclonal functional repertoire of Ag-specific T cells secreting IFN-␥ and/or perforin. The bona fide Ag, in contrast to anti-Id, induced an Ep-CAM-specific Th1-biased Ab and a long-lasting proliferative T-cell response. Thus, the Ep-CAM protein seems to be preferable, as compared with anti-Id, for vaccine development. Moreover, several immunogenic MHC class I-and II-restricted Ep-CAM epitopes were identified that might be of importance for future rational vaccine design. 6 Unpublished data. Abbreviations: NED, no evidence of disease; LTR, local tumor recurrence; DM, distant metastasis.
* Survival is shown from start of immunization until follow-up in patients alive (ϩ) or until death.
† A positive response was detected at one time point only. ‡ Died of disease (pneumonia) not related to CRC.
